Trial Design and Optimal Determination of CNS Activity of Small Molecule Targeted Therapy in NSCLC
Recommended Citation
Jennings EM, Camidge DR, Gadgeel S, and Barker S. Trial Design and Optimal Determination of CNS Activity of Small Molecule Targeted Therapy in NSCLC. Clin Lung Cancer 2023; 25(2):91-99.
Document Type
Article
Publication Date
3-1-2024
Publication Title
Clinical lung cancer
Abstract
Central nervous system (CNS) metastases are frequently diagnosed in patients with non-small cell lung cancer (NSCLC). Only recently, clinical trials are broadening eligibility to include patients with brain metastases, offering the potential for some assessment of CNS efficacy to be made. In this work we aim to review the available information on the activity of small molecule targeted drugs for advanced NSCLC with respect to CNS metastases. We analyze a framework for evaluation assessment regarding trials of systemic agents being conducted in patients with, or at risk from, CNS metastases, and provide examples of NSCLC targeted therapies evaluated in the CNS.
Medical Subject Headings
Humans; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Brain Neoplasms; Central Nervous System Neoplasms
PubMed ID
38135566
ePublication
ePub ahead of print
Volume
25
Issue
2
First Page
91
Last Page
99
